A Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
Phase of Trial: Phase III
Latest Information Update: 11 Feb 2019
At a glance
- Drugs Ibrutinib (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 23 May 2018 Status changed from not yet recruiting to recruiting.
- 05 Apr 2018 Planned initiation date changed from 30 Mar 2018 to 27 Apr 2018.
- 28 Mar 2018 New trial record